Nature Medicine, Published online: 05 September 2025; doi:10.1038/s41591-025-03945-8
A report from the first 2,000 newborns enrolled in the Early Check program, which offered genome screening covering 198 genes associated with early-onset diseases, shows the feasibility and potential clinical utility of the approach, leading to 28 true positive results.- September 5, 2025
- 0 Comment
Nature Medicine, Published online: 05 September 2025; doi:10.1038/s41591-025-03938-7
A digital twin, or virtual organ, can help clinicians and patients make better decisions, and can even help in the design of more-efficient clinical trials.- September 5, 2025
- 0 Comment
Nature Medicine, Published online: 05 September 2025; doi:10.1038/s41591-025-03915-0
We studied people with obesity involved in the SURMOUNT-1 trial of the dual GLP-1 and GIP receptor agonist, tirzepatide. People with pathogenic variants of the gene encoding the melanocortin 4 receptor (MC4R) lost a similar amount of weight to people with an intact gene, demonstrating that tirzepatide is effective in MC4R deficiency.- September 5, 2025
- 0 Comment
Nature Medicine, Published online: 05 September 2025; doi:10.1038/s41591-025-03940-z
Imaging data support the clinical effects of RNA interference agent vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy — and point to a potential new role for echocardiographic parameters in monitoring individual treatment responses.- September 5, 2025
- 0 Comment
Nature Medicine, Published online: 04 September 2025; doi:10.1038/s41591-025-03935-w
In the secondary endpoint analysis of the phase 3 SONIA trial, circulating tumor DNA (ctDNA) analysis showed that a pretreatment aneuploidy-based high ctDNA level in patients with advanced breast cancer was associated with benefit from first-line treatment with CDK4/6 inhibitors.- September 4, 2025
- 0 Comment
Nature Medicine, Published online: 04 September 2025; doi:10.1038/s41591-025-03885-3
In this single-arm phase 2 trial in patients with HR+HER2− advanced breast cancer, treatment with the HER3-targeting antibody–drug conjugate paritumab deruxtecan led to encouraging objective response rates, and comprehensive exploratory analyses indicate potential biomarkers of response.- September 4, 2025
- 0 Comment
Nature Medicine, Published online: 04 September 2025; doi:10.1038/s41591-025-03921-2
Luis Diaz describes how a molecular blood assay revealed the tiniest traces of DNA from a tumor, changing how we monitor cancer.- September 4, 2025
- 0 Comment
Nature Medicine, Published online: 04 September 2025; doi:10.1038/s41591-025-03908-z
Improving the evidence base for COVID-19 vaccines- September 4, 2025
- 0 Comment
- September 2, 2025
- 0 Comment
- September 2, 2025
- 0 Comment